APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radionuclide Drug Conjugate(RDC)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Radionuclide Drug Conjugate(RDC) Industry Growth and Trends Forecast to 2032

28 December 2025101 pages

Choose your research edition.

Industry ResearchRadionuclide Drug Conjugate(RDC) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Radionuclide Drug Conjugate(RDC) Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Radionuclide Drug Conjugate(RDC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radionuclide Drug Conjugate(RDC) Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Radionuclide Drug Conjugate(RDC) Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

According to APO Research, the global Radionuclide Drug Conjugate(RDC) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Radionuclide Drug Conjugate(RDC) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Radionuclide Drug Conjugate(RDC) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radionuclide Drug Conjugate(RDC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Radionuclide Drug Conjugate(RDC) market include China Tongfang Pharmaceuticals, Zhihe Biotechnology, Yuanda Pharmaceuticals, Novartis, Kelun Biotech, Hengrui, Fulian Pharmaceuticals, Dongcheng Pharmaceuticals and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Radionuclide Drug Conjugate(RDC) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Radionuclide Drug Conjugate(RDC) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Radionuclide Drug Conjugate(RDC) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Radionuclide Drug Conjugate(RDC).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Radionuclide Drug Conjugate(RDC) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Radionuclide Drug Conjugate(RDC) Market by Company

China Tongfang Pharmaceuticals

Zhihe Biotechnology

Yuanda Pharmaceuticals

Novartis

Kelun Biotech

Hengrui

Fulian Pharmaceuticals

Dongcheng Pharmaceuticals

Bayer

Telix Pharmaceuticals

Lantheus

Curium

Radionuclide Drug Conjugate(RDC) Segment by Type

Therapy

Diagnosis

Radionuclide Drug Conjugate(RDC) Segment by Application

Prostate Cancer

Neuroendocrine Cancer

Other

Radionuclide Drug Conjugate(RDC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radionuclide Drug Conjugate(RDC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radionuclide Drug Conjugate(RDC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radionuclide Drug Conjugate(RDC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Radionuclide Drug Conjugate(RDC) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Radionuclide Drug Conjugate(RDC) Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Radionuclide Drug Conjugate(RDC) Market Share by Region (2021-2026) Table 4. Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Radionuclide Drug Conjugate(RDC) Market Share by Region (2027-2032) Table 6. Global Radionuclide Drug Conjugate(RDC) Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Radionuclide Drug Conjugate(RDC) Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Radionuclide Drug Conjugate(RDC) Market Size Share by Type (2021-2026) Table 9. Global Radionuclide Drug Conjugate(RDC) Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Radionuclide Drug Conjugate(RDC) Market Size Share Forecasted by Type (2027-2032) Table 11. North America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Radionuclide Drug Conjugate(RDC) Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Radionuclide Drug Conjugate(RDC) Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Radionuclide Drug Conjugate(RDC) Market Size Share by Application (2021-2026) Table 24. Global Radionuclide Drug Conjugate(RDC) Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Radionuclide Drug Conjugate(RDC) Market Size Share Forecasted by Application (2027-2032) Table 26. North America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Radionuclide Drug Conjugate(RDC) Industry Trends Table 37. Radionuclide Drug Conjugate(RDC) Industry Drivers Table 38. Radionuclide Drug Conjugate(RDC) Industry Opportunities and Challenges Table 39. Radionuclide Drug Conjugate(RDC) Industry Restraints Table 40. Global Radionuclide Drug Conjugate(RDC) Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Company (2021-2026) Table 42. Global Radionuclide Drug Conjugate(RDC) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Radionuclide Drug Conjugate(RDC) Key Company Headquarters & Area Served Table 44. Global Radionuclide Drug Conjugate(RDC) Company, Product Type & Application Table 45. Global Radionuclide Drug Conjugate(RDC) Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Radionuclide Drug Conjugate(RDC) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. China Tongfang Pharmaceuticals Company Information Table 49. China Tongfang Pharmaceuticals Business Overview Table 50. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 52. China Tongfang Pharmaceuticals Recent Development Table 53. Zhihe Biotechnology Company Information Table 54. Zhihe Biotechnology Business Overview Table 55. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio Table 57. Zhihe Biotechnology Recent Development Table 58. Yuanda Pharmaceuticals Company Information Table 59. Yuanda Pharmaceuticals Business Overview Table 60. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 62. Yuanda Pharmaceuticals Recent Development Table 63. Novartis Company Information Table 64. Novartis Business Overview Table 65. Novartis Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio Table 67. Novartis Recent Development Table 68. Kelun Biotech Company Information Table 69. Kelun Biotech Business Overview Table 70. Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio Table 72. Kelun Biotech Recent Development Table 73. Hengrui Company Information Table 74. Hengrui Business Overview Table 75. Hengrui Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio Table 77. Hengrui Recent Development Table 78. Fulian Pharmaceuticals Company Information Table 79. Fulian Pharmaceuticals Business Overview Table 80. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 82. Fulian Pharmaceuticals Recent Development Table 83. Dongcheng Pharmaceuticals Company Information Table 84. Dongcheng Pharmaceuticals Business Overview Table 85. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 87. Dongcheng Pharmaceuticals Recent Development Table 88. Bayer Company Information Table 89. Bayer Business Overview Table 90. Bayer Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio Table 92. Bayer Recent Development Table 93. Telix Pharmaceuticals Company Information Table 94. Telix Pharmaceuticals Business Overview Table 95. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio Table 97. Telix Pharmaceuticals Recent Development Table 98. Lantheus Company Information Table 99. Lantheus Business Overview Table 100. Lantheus Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio Table 102. Lantheus Recent Development Table 103. Curium Company Information Table 104. Curium Business Overview Table 105. Curium Radionuclide Drug Conjugate(RDC) Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Curium Radionuclide Drug Conjugate(RDC) Product Portfolio Table 107. Curium Recent Development Table 108. North America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. North America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026) & (US$ Million) Table 110. North America Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2026) Table 111. North America Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. North America Radionuclide Drug Conjugate(RDC) Market Share Forecast by Country (2027-2032) Table 113. Europe Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026) & (US$ Million) Table 115. Europe Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2026) Table 116. Europe Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. Europe Radionuclide Drug Conjugate(RDC) Market Share Forecast by Country (2027-2032) Table 118. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 119. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026) & (US$ Million) Table 120. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2026) Table 121. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 122. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Share Forecast by Country (2027-2032) Table 123. Latin America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Latin America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026) & (US$ Million) Table 125. Latin America Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2026) Table 126. Latin America Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Latin America Radionuclide Drug Conjugate(RDC) Market Share Forecast by Country (2027-2032) Table 128. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026) & (US$ Million) Table 130. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2026) Table 131. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Share Forecast by Country (2027-2032) Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Radionuclide Drug Conjugate(RDC) Product Image Figure 3. Global Radionuclide Drug Conjugate(RDC) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Radionuclide Drug Conjugate(RDC) Market Size (2021-2032) & (US$ Million) Figure 5. Global Radionuclide Drug Conjugate(RDC) Market Share by Region: 2025 VS 2032 Figure 6. Global Radionuclide Drug Conjugate(RDC) Market Share by Region (2021-2032) Figure 7. North America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Therapy Image Figure 13. Global Therapy Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Diagnosis Image Figure 15. Global Diagnosis Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Radionuclide Drug Conjugate(RDC) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Radionuclide Drug Conjugate(RDC) Market Share by Type 2025 VS 2032 Figure 18. North America Radionuclide Drug Conjugate(RDC) Market Size Share by Type (2021-2032) Figure 19. Europe Radionuclide Drug Conjugate(RDC) Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Share by Type (2021-2032) Figure 21. Latin America Radionuclide Drug Conjugate(RDC) Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Share by Type (2021-2032) Figure 23. Prostate Cancer Image Figure 24. Global Prostate Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Neuroendocrine Cancer Image Figure 26. Global Neuroendocrine Cancer Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Other Image Figure 28. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Global Radionuclide Drug Conjugate(RDC) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Radionuclide Drug Conjugate(RDC) Market Share by Application 2025 VS 2032 Figure 31. North America Radionuclide Drug Conjugate(RDC) Market Size Share by Application (2021-2032) Figure 32. Europe Radionuclide Drug Conjugate(RDC) Market Size Share by Application (2021-2032) Figure 33. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Share by Application (2021-2032) Figure 34. Latin America Radionuclide Drug Conjugate(RDC) Market Size Share by Application (2021-2032) Figure 35. Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Share by Application (2021-2032) Figure 36. Global Top 5 and 10 Radionuclide Drug Conjugate(RDC) Players Market Share by Revenue in 2025 Figure 37. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 38. North America Radionuclide Drug Conjugate(RDC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 39. North America Radionuclide Drug Conjugate(RDC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 40. North America Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2032) Figure 41. Europe Radionuclide Drug Conjugate(RDC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 42. Europe Radionuclide Drug Conjugate(RDC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 43. Europe Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2032) Figure 44. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 45. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 46. Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2032) Figure 47. Latin America Radionuclide Drug Conjugate(RDC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Latin America Radionuclide Drug Conjugate(RDC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Latin America Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2032) Figure 50. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 51. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Share by Country: 2021 VS 2025 VS 2032 Figure 52. Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Share by Country (2021-2032) Figure 53. Years Considered Figure 54. Research Process Figure 55. Key Executives Interviewed

Scope & coverage.

Types
  • Therapy
  • Diagnosis
Applications
  • Prostate Cancer
  • Neuroendocrine Cancer
  • Other
Companies covered
  • China Tongfang Pharmaceuticals
  • Zhihe Biotechnology
  • Yuanda Pharmaceuticals
  • Novartis
  • Kelun Biotech
  • Hengrui
  • Fulian Pharmaceuticals
  • Dongcheng Pharmaceuticals
  • Bayer
  • Telix Pharmaceuticals
  • Lantheus
  • Curium

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Radionuclide Drug Conjugate(RDC) Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2032)
  5. 1.4.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2021-2026)
  6. 1.4.2 Global Radionuclide Drug Conjugate(RDC) Market Size by Region (2027-2032)
  7. 1.5 Key Regions Radionuclide Drug Conjugate(RDC) Market Size (2021-2032)
  8. 1.5.1 North America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (2021-2032)
2 Radionuclide Drug Conjugate(RDC) Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Therapy
  3. 2.1.2 Diagnosis
  4. 2.2 Global Radionuclide Drug Conjugate(RDC) Market Size by Type
  5. 2.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Radionuclide Drug Conjugate(RDC) Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Radionuclide Drug Conjugate(RDC) Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Radionuclide Drug Conjugate(RDC) Market Size by Regions
  9. 2.3.1 North America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Type (2021-2026)
3 Radionuclide Drug Conjugate(RDC) Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Prostate Cancer
  3. 3.1.2 Neuroendocrine Cancer
  4. 3.1.3 Other
  5. 3.2 Global Radionuclide Drug Conjugate(RDC) Market Size by Application
  6. 3.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Radionuclide Drug Conjugate(RDC) Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Radionuclide Drug Conjugate(RDC) Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Radionuclide Drug Conjugate(RDC) Market Size by Regions
  10. 3.3.1 North America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Radionuclide Drug Conjugate(RDC) Industry Trends
  2. 4.2 Radionuclide Drug Conjugate(RDC) Industry Drivers
  3. 4.3 Radionuclide Drug Conjugate(RDC) Industry Opportunities and Challenges
  4. 4.4 Radionuclide Drug Conjugate(RDC) Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Radionuclide Drug Conjugate(RDC) Revenue (2021-2026)
  2. 5.2 Global Radionuclide Drug Conjugate(RDC) Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Radionuclide Drug Conjugate(RDC) Key Company Headquarters & Area Served
  4. 5.4 Global Radionuclide Drug Conjugate(RDC) Company, Product Type & Application
  5. 5.5 Global Radionuclide Drug Conjugate(RDC) Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Radionuclide Drug Conjugate(RDC) Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Radionuclide Drug Conjugate(RDC) Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Radionuclide Drug Conjugate(RDC) Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 China Tongfang Pharmaceuticals
  2. 6.1.1 China Tongfang Pharmaceuticals Company Information
  3. 6.1.2 China Tongfang Pharmaceuticals Business Overview
  4. 6.1.3 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  6. 6.1.5 China Tongfang Pharmaceuticals Recent Developments
  7. 6.2 Zhihe Biotechnology
  8. 6.2.1 Zhihe Biotechnology Company Information
  9. 6.2.2 Zhihe Biotechnology Business Overview
  10. 6.2.3 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Portfolio
  12. 6.2.5 Zhihe Biotechnology Recent Developments
  13. 6.3 Yuanda Pharmaceuticals
  14. 6.3.1 Yuanda Pharmaceuticals Company Information
  15. 6.3.2 Yuanda Pharmaceuticals Business Overview
  16. 6.3.3 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  18. 6.3.5 Yuanda Pharmaceuticals Recent Developments
  19. 6.4 Novartis
  20. 6.4.1 Novartis Company Information
  21. 6.4.2 Novartis Business Overview
  22. 6.4.3 Novartis Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Novartis Radionuclide Drug Conjugate(RDC) Product Portfolio
  24. 6.4.5 Novartis Recent Developments
  25. 6.5 Kelun Biotech
  26. 6.5.1 Kelun Biotech Company Information
  27. 6.5.2 Kelun Biotech Business Overview
  28. 6.5.3 Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Portfolio
  30. 6.5.5 Kelun Biotech Recent Developments
  31. 6.6 Hengrui
  32. 6.6.1 Hengrui Company Information
  33. 6.6.2 Hengrui Business Overview
  34. 6.6.3 Hengrui Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Hengrui Radionuclide Drug Conjugate(RDC) Product Portfolio
  36. 6.6.5 Hengrui Recent Developments
  37. 6.7 Fulian Pharmaceuticals
  38. 6.7.1 Fulian Pharmaceuticals Company Information
  39. 6.7.2 Fulian Pharmaceuticals Business Overview
  40. 6.7.3 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  42. 6.7.5 Fulian Pharmaceuticals Recent Developments
  43. 6.8 Dongcheng Pharmaceuticals
  44. 6.8.1 Dongcheng Pharmaceuticals Company Information
  45. 6.8.2 Dongcheng Pharmaceuticals Business Overview
  46. 6.8.3 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  48. 6.8.5 Dongcheng Pharmaceuticals Recent Developments
  49. 6.9 Bayer
  50. 6.9.1 Bayer Company Information
  51. 6.9.2 Bayer Business Overview
  52. 6.9.3 Bayer Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Bayer Radionuclide Drug Conjugate(RDC) Product Portfolio
  54. 6.9.5 Bayer Recent Developments
  55. 6.10 Telix Pharmaceuticals
  56. 6.10.1 Telix Pharmaceuticals Company Information
  57. 6.10.2 Telix Pharmaceuticals Business Overview
  58. 6.10.3 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Portfolio
  60. 6.10.5 Telix Pharmaceuticals Recent Developments
  61. 6.11 Lantheus
  62. 6.11.1 Lantheus Company Information
  63. 6.11.2 Lantheus Business Overview
  64. 6.11.3 Lantheus Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Lantheus Radionuclide Drug Conjugate(RDC) Product Portfolio
  66. 6.11.5 Lantheus Recent Developments
  67. 6.12 Curium
  68. 6.12.1 Curium Company Information
  69. 6.12.2 Curium Business Overview
  70. 6.12.3 Curium Radionuclide Drug Conjugate(RDC) Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Curium Radionuclide Drug Conjugate(RDC) Product Portfolio
  72. 6.12.5 Curium Recent Developments
7 North America
  1. 7.1 North America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
  3. 7.3 North America Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
  3. 8.3 Europe Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
  3. 10.3 South America Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Radionuclide Drug Conjugate(RDC) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst